Here are six takeaways:
1. This merging acts as an exchanging of Kuros shares for new Cytos shares, subject to shareholder approval and other customary conditions.
2. Cytos is listed on the main segment of the Swiss stock exchange, while Kuros is a privately-held company based in Zurich, Switzerland.
3. The new name of the combined entity will be Kuros Biosciences AG.
4. As a result of the combination, shareholders of Cytos will have ownership in a leading biosciences company in the field of tissue repair and regeneration.
5. Kuros Biosurgery focuses on the development of innovative products for tissue repair and regeneration and is a spin-off of the Swiss Federal Institute of Technology.
